Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market Research Report – Segmentation by End-Users (Hospitals, Specialty Clinics, Research Institutes, and Others); Region – Size, Share, Growth Analysis |Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-16125
Format:
Region: Global
Chapter 1. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET – Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET – By Payment Method
6.1. Debit Card
6.2. Credit Card
6.3. e-Wallet
6.4. Automated Clearing House (ACH)
Chapter 7. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET– By End User
7.1. Hospitals
7.2. Speciality Clinic
7.3. Research Institue
7.4. Others
Chapter 8. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET - By Geography – Market Size, Forecast, Trends & Insights
8.1. North America
8.1.1. By Country
8.1.1.1. U.S.A.
8.1.1.2. Canada
8.1.1.3. Mexico
8.1.2. By Payment Method
8.1.3. By End User
8.1.5. Countries & Segments - Market Attractiveness Analysis
8.2. Europe
8.2.1. By Country
8.2.1.1. U.K.
8.2.1.2. Germany
8.2.1.3. France
8.2.1.4. Italy
8.2.1.5. Spain
8.2.1.6. Rest of Europe
8.2.2. By Payment Method
8.2.3. By End User
8.2.4. Countries & Segments - Market Attractiveness Analysis
8.3. Asia Pacific
8.3.1. By Country
8.3.1.1. China
8.3.1.2. Japan
8.3.1.3. South Korea
8.3.1.4. India
8.3.1.5. Australia & New Zealand
8.3.1.6. Rest of Asia-Pacific
8.3.2. By Payment Method
8.3.3. By End User
8.3.4. Countries & Segments - Market Attractiveness Analysis
8.4. South America
8.4.1. By Country
8.4.1.1. Brazil
8.4.1.2. Argentina
8.4.1.3. Colombia
8.4.1.4. Chile
8.4.1.5. Rest of South America
8.4.2. By Payment Method
8.4.3. By End User
8.4.4. Countries & Segments - Market Attractiveness Analysis
8.5. Middle East & Africa
8.5.1. By Country
8.5.1.1. United Arab Emirates (UAE)
8.5.1.2. Saudi Arabia
8.5.1.3. Qatar
8.5.1.4. Israel
8.5.1.5. South Africa
8.5.1.6. Nigeria
8.5.1.7. Kenya
8.5.1.8. Egypt
8.5.1.8. Rest of MEA
8.5.2. By Payment Method
8.5.3. By End User
8.5.4. Countries & Segments - Market Attractiveness Analysis
Chapter 9. GLOBAL CHEMOTHERAPY - BASED HEPATOCELLULAR CARCINOMA (HCC) TREATMENT MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
9.1. Bayer AG
9.2. Eisai Co., Ltd.
9.3. Bristol Myers Squibb (BMS)
9.4. Merck & Co., Inc. (MSD)
9.5. Roche
9.6. AstraZeneca
9.7. Jiangsu Hengrui Medicine Co., Ltd.
9.8. CStone Pharmaceuticals
9.9. BeiGene
9.10. Ono Pharmaceutical Co., Ltd.
Download Sample
Choose License Type
2500
4250
5250
6900
Frequently Asked Questions
The global chemotherapy-based hepatocellular carcinoma (HCC) treatment market was valued at USD 400 million and is projected to reach a market size of USD 601.45 million by the end of 2030. Over the forecast period of 2024–2030, the market is projected to grow at a CAGR of 6%.
A high number of cancer cases, advancements in R&D activities, and personalized medicine are the main factors propelling the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market.
Based on End-Users, the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market is segmented into Hospitals, Specialty Clinics, Research Institutes, and Others.
North America is the most dominant region for the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market.
Bayer AG, Eisai Co., Ltd., and Bristol Myers Squibb (BMS) are the key players operating in the Global Chemotherapy-based Hepatocellular Carcinoma (HCC) Treatment Market.
